CoChat
Sign Up
Cited by 53

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Structures of Angptl3 and Angptl4, modulators of triglyceride levels and coronary artery disease

Biterova, Ekaterina, Esmaeeli, Mariam, Alanen, Heli I., Saaranen, Mirva, Ruddock, Lloyd W.·2018·Scientific Reports
DOI 10.1038/s41598-018-25237-7PMC PMC5928061
Open this paper in CoChat — free account

Abstract

Coronary artery disease is the most common cause of death globally and is linked to a number of risk factors including serum low density lipoprotein, high density lipoprotein, triglycerides and lipoprotein(a). Recently two proteins, angiopoietin-like protein 3 and 4, have emerged from genetic studies as being factors that significantly modulate plasma triglyceride levels and coronary artery disease. The exact function and mechanism of action of both proteins remains to be elucidated, however, mutations in these proteins results in up to 34% reduction in coronary artery disease and inhibition of function results in reduced plasma triglyceride levels. Here we report the crystal structures of the fibrinogen-like domains of both proteins. These structures offer new insights into the reported loss of function mutations, the mechanisms of action of the proteins and open up the possibility for the rational design of low molecular weight inhibitors for intervention in coronary artery disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-018-25237-7

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Crystal structure of the fibrinogen-like domains of Angptl3 and Angptl4. (A) Schematic of Angiopoietin-like protein domain architecture. Each angiopoietin and angiopoietin-like protein (except Angptl8) contains an N-terminal region predicted to be intrinsically disordered, a coiled-coil region and a C-terminal fibrinogen-like domain. (B) Structure of Angptl3 (left) and Angptl4 (right) fibrinogen-like domains. Each can be split into three subdomains A, B and P. Each structure is colored according to secondary structure elements with α-helices in gold (Angptl3) and violet (Angptl4), β-strands in cyan (Angptl4) and green (Angptl4) and loops in grey. Missing sections in the loops are indicated by dashed lines. Secondary structure elements are labeled and the N- and C-termini are indicated. (C) Electrostatic surface potential of Angptl3, the orientation is equivalent to that in panel B and rotated 90° around horizontal axis to see the underside of the P subdomain. Negative charge is shown in red and positive in blue. (D) As panel C but Angptl4.
Figure 1 Crystal structure of the fibrinogen-like domains of Angptl3 and Angptl4. (A) Schematic of Angiopoietin-like protein domain architecture. Each angiopoietin and angiopoietin-like protein (except Angptl8) contains an N-terminal region predicted to be intrinsically disordered, a coiled-coil region and a C-terminal fibrinogen-like domain. (B) Structure of Angptl3 (left) and Angptl4 (right) fibrinogen-like domains. Each can be split into three subdomains A, B and P. Each structure is colored according to secondary structure elements with α-helices in gold (Angptl3) and violet (Angptl4), β-strands in cyan (Angptl4) and green (Angptl4) and loops in grey. Missing sections in the loops are indicated by dashed lines. Secondary structure elements are labeled and the N- and C-termini are indicated. (C) Electrostatic surface potential of Angptl3, the orientation is equivalent to that in panel B and rotated 90° around horizontal axis to see the underside of the P subdomain. Negative charge is shown in red and positive in blue. (D) As panel C but Angptl4.CC BY · PubMed Central
Figure 2 Comparison of the Angptl3 and Angptl4 fibrinogen-like domains with angiopoietins. (A) Overlay of the Cα-trace of Angptl3 (blue, left) and Angptl4 (green, right) with those of Ang1 (yellow) and Ang2 (violet). (B) Comparison with Ca2+ binding site of Ang1 (light yellow) and Ang2 (light violet) of the equivalent region in Angptl3 (blue, top) and Angptl4 (green, bottom). Residues involved in Ca2+ binding are shown in stick representation and colored similarly to the protein they belong. Ca2+ ions are shown in ball representation. (C) Alignment of the proteins shown in panel A. Cysteines are highlighted in yellow and conserved amino acids in blue. The P subdomain is boxed and the Asp involved in calcium binding in Ang1 and Ang2 are indicated with arrowheads.
Figure 2 Comparison of the Angptl3 and Angptl4 fibrinogen-like domains with angiopoietins. (A) Overlay of the Cα-trace of Angptl3 (blue, left) and Angptl4 (green, right) with those of Ang1 (yellow) and Ang2 (violet). (B) Comparison with Ca2+ binding site of Ang1 (light yellow) and Ang2 (light violet) of the equivalent region in Angptl3 (blue, top) and Angptl4 (green, bottom). Residues involved in Ca2+ binding are shown in stick representation and colored similarly to the protein they belong. Ca2+ ions are shown in ball representation. (C) Alignment of the proteins shown in panel A. Cysteines are highlighted in yellow and conserved amino acids in blue. The P subdomain is boxed and the Asp involved in calcium binding in Ang1 and Ang2 are indicated with arrowheads.CC BY · PubMed Central
Figure 3 Structural analysis of mutations in Angptl3 which cause loss of function. (A) Angptl3 fibrinogen-like domain crystal structure with the sites of loss of function mutations depicted in ball and stick representation and highlighted in red. (B) Close up views of the environment of the mutated amino acids in panel A. Mutated residues are shown in ball and stick representation and neighboring or interacting residues are in stick representation. Residues are colored according to their location in the secondary structure elements with nitrogen atoms in blue, oxygen in red and sulfur in yellow. Potential hydrogen bonds are depicted as solid black lines.
Figure 3 Structural analysis of mutations in Angptl3 which cause loss of function. (A) Angptl3 fibrinogen-like domain crystal structure with the sites of loss of function mutations depicted in ball and stick representation and highlighted in red. (B) Close up views of the environment of the mutated amino acids in panel A. Mutated residues are shown in ball and stick representation and neighboring or interacting residues are in stick representation. Residues are colored according to their location in the secondary structure elements with nitrogen atoms in blue, oxygen in red and sulfur in yellow. Potential hydrogen bonds are depicted as solid black lines.CC BY · PubMed Central
Figure 4 Structural analysis of mutations in Angptl4 which cause loss of function. (A) Angptl4 fibrinogen-like domain crystal structure with the sites of mutations resulting in lower triglyceride levels are indicated in red, mutations leading to the increase of triglyceride levels are shown in blue. (B) Close up views of the environment of the mutated amino acids in panel A. Residues are depicted and colored as in Fig. 3.
Figure 4 Structural analysis of mutations in Angptl4 which cause loss of function. (A) Angptl4 fibrinogen-like domain crystal structure with the sites of mutations resulting in lower triglyceride levels are indicated in red, mutations leading to the increase of triglyceride levels are shown in blue. (B) Close up views of the environment of the mutated amino acids in panel A. Residues are depicted and colored as in Fig. 3.CC BY · PubMed Central
Figure 5 Analysis of loss of function mutations (A) Coomassie stained SDS-PAGE gel of IMAC purified proteins. Upper gel Angptl3, lower gel Angptl4 (Supplementary Fig. 1 shows the full gels) (B) Thermal stability of purified wild-type Angptl3 determined by thermofluor. The insert panel shows the derivative of the change in fluorescence signal. Angptl3 shows cooperative unfolding.
Figure 5 Analysis of loss of function mutations (A) Coomassie stained SDS-PAGE gel of IMAC purified proteins. Upper gel Angptl3, lower gel Angptl4 (Supplementary Fig. 1 shows the full gels) (B) Thermal stability of purified wild-type Angptl3 determined by thermofluor. The insert panel shows the derivative of the change in fluorescence signal. Angptl3 shows cooperative unfolding.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 42

  1. Wang, H. et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388, 1775–1812 (2016). · DOI
  2. Nakanishi, R. et al. Current but not past smoking increases the risk of cardiac events: insights from coronary computed tomographic angiography. Eur Heart J 36, 1031–1040 (2015). · DOI
  3. Lehrke, M. & Marx, N. Diabetes mellitus and heart failure. Am J Med 130, S40–S50 (2017). · DOI
  4. Khera, A. V. & Kathiresan, S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet 18, 331–344 (2017). · DOI · Paper page
  5. Kivimäki, M. et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet 380, 1491–1497 (2012). · DOI
  6. Cosselman, K. E., Navas-Acien, A. & Kaufman, J. D. Environmental factors in cardiovascular disease. Nat Rev Cardiol 12, 627–642 (2015). · DOI · Paper page
  7. Nordestgaard, B. D. & Varbo, A. Triglycerides and cardiovascular disease. Lancet 384, 626–635 (2014). · DOI · Paper page
  8. Reiner, Ž. Hypertriglycerideaemia and risk of coronary artery disease. Nat Rev Cardiol 14, 401–411 (2017). · DOI
  9. Natarajan, P. & Kathiresan, S. PCSK9 inhibitors. Cell 165, 1037 (2016). · DOI
  10. Thomas, M. & Augustin, H. G. The role of the angiopoietins in vascular morphogenesis. Angiogenesis 12, 125–137 (2009). · DOI
  11. Ono, M. et al. Protein region important for regulation of lipid metabolism in Angiopoietin-like 3 (ANGPTL3): ANGPTL3 is cleaved and activated in vivo. J Biol Chem 278, 41804–41809 (2003). · DOI · Paper page
  12. Quagliarini, F. et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA 109, 19751–19756 (2012). · DOI · Paper page
  13. Chomel, C. et al. Interaction of the coiled-coil domain with glycosaminoglycans protects angiopoietin-like 4 from proteolysis and regulates its antiangiogenic activity. FASEB J 23, 940–949 (2009). · DOI
  14. Arca, M., Minicocci, I. & Maranghi, M. The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism. Curr Opin Lipidol 24, 313–320 (2013). · DOI
  15. Grootaert, C., Van de Wiele, T., Verstraete, W., Bracke, M. & Vanhoecke, B. Angiopoietin-like protein 4: health effects, modulating agents and structure-function relationships. Expert Rev Proteomics 9, 181–199 (2012). · DOI
  16. Goh, Y. Y. et al. Angiopoietin-like 4 interacts with matrix proteins to modulate wound healing. J Biol Chem 285, 32999–33009 (2010). · DOI
  17. Chong, H. C. et al. Angiopoietin-like 4 stimulates STAT3-mediated iNOS expression and enhances angiogenesis to accelerate would healing in diabetic mice. Mol Ther 22, 1593–1604 (2014). · DOI
  18. Musunuru, K. & Kathiresan, S. Is ANGPLT3 the next PCSK9? Nat Rev Endocrinol 13, 503–504 (2017). · DOI
  19. Romeo, S. et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 119, 70–79 (2009).
  20. Pisciotta, L. et al. Characterization of three kindreds with familial combined hypolipidemia caused by loss-of-function mutations in ANGPTL3. Circ Cardiovasc Genet 5, 42–50 (2012). · DOI · Paper page
  21. Wang, X., Wang, D. & Shan, Z. Clinical and genetic analysis of a family diagnosed with familial hypobetalipoproteinemia in which the proband was diagnosed with diabetes mellitus. Atherosclerosis 239, 552–556 (2017). · DOI
  22. Romeo, S. et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 39, 513–516 (2007). · DOI · Paper page
  23. Smart-Halajko, M. C. et al. ANGPTL4 variants E40K and T266M are associated with lower fasting triglyceride levels in non-Hispanic white Americans from the Look AHEAD clinical trial. BMC Med Genet 12, 89 (2011). · DOI
  24. Shimizugawa, T. et al. ANGPTL3 decrease very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase. J Biol Chem 277, 33742–33748 (2002). · DOI · Paper page
  25. Yoshida, K., Shimizugawa, T., Ono, M. & Furukawa, H. Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase. J Lipid Res 43, 1770–1772 (2002). · DOI · Paper page
  26. Holm, L. & Rosenström, P. Dali server: conservation mapping in 3D. Nucl Acids Res 38, W545–549 (2010). · DOI · Paper page
  27. Yu, X. et al. Structural basis for angiopoietin-1 mediated signaling initiation. Proc Natl Acad Sci USA 110, 7205–7210 (2013). · DOI
  28. Barton, W. A., Tzvetkova, D. & Nikolov, D. B. Structure of the angiopoietin-2 receptor binding domain and identification of surfaces involved in Tie2 recognition. Structure 13, 825–832 (2005). · DOI
  29. Garlatti, V. et al. Structural Basis for innate immune sensing by M-Ficolin and its control by a pH-dependent conformational switch. J Biol Chem 282, 35814–35820 (2007). · DOI
  30. Garlatti, V. et al. Structural insights into the innate immune recognition specificities of L- and H-Ficolins. EMBO J 26, 623–633 (2007). · DOI
  31. Kairies, N. et al. The 2.0-A crystal structure of tachylectin 5A provides evidence for the common origin of the innate immunity and the blood coagulation systems. Proc Natl Acad Sci USA 98, 13519–13524 (2001). · DOI
  32. Koopman, J., Haverkate, F., Briet, E. & Lord, S. T. A congenitally abnormal fibrinogen (Vlissingen) with 6-base deletion of γ-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 266, 13456–13461 (1991). · DOI
  33. Kawabata, S. & Tsuda, R. Molecular basis of non-self recognition by horseshoe crab tachylectins. Biochim Biophys Acta 1572, 414–421 (2002). · DOI
  34. Pósfai, G. et al. Emergent properties of reduced-genome Escherichia coli. Science 312, 1044–1046 (2006). · DOI
  35. Gaciarz, A. et al. Systematic screening of soluble expression of antibody fragments in the cytoplasm of E. coli. Micro Cell Fact 15, 22 (2016). · DOI · Paper page
  36. Gaciarz, A. & Ruddock, L.W. Complementary determining regions and frameworks contribute to the disulfide bond independent folding of intrinsically stable scFv. PLoS One 12, e0189964 (2017). · DOI
  37. Svensson, O., Monaco, S., Popov, A. N., Nurizzo, D. & Bowler, M. W. Fully automatic characterization and data collection from crystals of biological macromolecules. Acta Cryst D71, 1757–1767 (2015).
  38. Kabsch, W. XDS. Acta Cryst D66, 125–132 (2010).
  39. McCoy, A. J. et al. Phaser crystallographic software. J Appl Crystallogr 40, 658–674 (2007). · DOI · Paper page
  40. Emsley, P., Lohkamp, B., Scott, W. & Cowtan, K. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66, 486–501 (2010). · DOI · Paper page
  41. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Cryst D66, 16–21 (2010).
  42. Pettersen, E. F. et al. UCSF Chimera–a visualization system for exploratory research and analysis. J Comput Chem. 25, 1605–12 (2004). · DOI

Cited by

Sorted by citations

See all 53

Metadata

Authors
Biterova, E., Esmaeeli, M., Alanen, H. I., Saaranen, M., & Ruddock, L. W.
ORCID
Saaranen, Mirva
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2018-04-30
Volume
8
Issue
1
ISSN
2045-2322
DOI
10.1038/s41598-018-25237-7
PMC
PMC5928061
Cited by
53
References
14
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review